相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expression of the Homeobox Gene HOXA9 in Ovarian Cancer Induces Peritoneal Macrophages to Acquire an M2 Tumor-Promoting Phenotype
Song Yi Ko et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Bridget Charbonneau et al.
CANCER RESEARCH (2014)
Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
Lavakumar Karyampudi et al.
CANCER RESEARCH (2014)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
Darin A. Wick et al.
CLINICAL CANCER RESEARCH (2014)
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2014)
Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome
Bridget Charbonneau et al.
CANCER IMMUNOLOGY RESEARCH (2014)
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
S. B. Kaye et al.
ANNALS OF ONCOLOGY (2013)
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
S. Bellone et al.
BRITISH JOURNAL OF CANCER (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Michael Kalos et al.
IMMUNITY (2013)
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Paul Sabbatini et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer
Ellen L. Goode et al.
PLOS ONE (2013)
The Ratios of CD8+ T Cells to CD4+ CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
Claudia C. Preston et al.
PLOS ONE (2013)
CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg
Maha Ayyoub et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma
Sumit Agarwal et al.
ONCOIMMUNOLOGY (2013)
Breast-feeding and risk of epithelial ovarian cancer
S. J. Jordan et al.
CANCER CAUSES & CONTROL (2012)
Immunotherapy with IL-10-and IFN-γ-producing CD4 effector cells modulate Natural and Inducible CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer
Mark J. Dobrzanski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
Hagen Kulbe et al.
CANCER RESEARCH (2012)
Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants
Kristin L. White et al.
CANCER RESEARCH (2012)
Interleukin-6 signaling pathway in targeted therapy for cancer
Yuqi Guo et al.
CANCER TREATMENT REVIEWS (2012)
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer
Julie S. Nielsen et al.
CLINICAL CANCER RESEARCH (2012)
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K. Fizazi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies
Nicole S. Nevadunsky et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2012)
Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer: A Pilot Study
Stephen E. Wright et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
Celeste Leigh Pearce et al.
LANCET ONCOLOGY (2012)
Paraneoplastic Thrombocytosis in Ovarian Cancer
Rebecca L. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis
Cecile Le Page et al.
PLOS ONE (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study
A. T. Toriola et al.
ANNALS OF ONCOLOGY (2011)
Genital powder exposure and the risk of epithelial ovarian cancer
Karin A. Rosenblatt et al.
CANCER CAUSES & CONTROL (2011)
Circulating Inflammation Markers and Risk of Epithelial Ovarian Cancer
Tess V. Clendenen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
Chi-Wen Lo et al.
CANCER RESEARCH (2011)
CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer
Elda Righi et al.
CANCER RESEARCH (2011)
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward et al.
CLINICAL CANCER RESEARCH (2011)
NFKB1 Insertion/Deletion Promoter Polymorphism Increases the Risk of Advanced Ovarian Cancer in a Chinese Population
Yaxin Fan et al.
DNA AND CELL BIOLOGY (2011)
The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer
Shelby M. King et al.
ENDOCRINE-RELATED CANCER (2011)
Perineal talc use and ovarian cancer risk: a case study of scientific standards in environmental epidemiology
Michael Huncharek et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2011)
Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer
Xiangdong Ma et al.
GYNECOLOGIC ONCOLOGY (2011)
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
K. Baumann et al.
GYNECOLOGIC ONCOLOGY (2011)
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
Rachel N. Grisham et al.
IMMUNOTHERAPY (2011)
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
James Krempski et al.
JOURNAL OF IMMUNOLOGY (2011)
Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study
Hui-Wen Lin et al.
LANCET ONCOLOGY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
The Anti-Interleukin-6 Antibody Siltuximab Down-Regulates Genes Implicated inTumorigenesis in Prostate Cancer Patients From a Phase I Study
Jayaprakash Karkera et al.
PROSTATE (2011)
Protective and pathogenic functions of macrophage subsets
Peter J. Murray et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
Shiqian Zhang et al.
BMC CANCER (2010)
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
N. Leffers et al.
BRITISH JOURNAL OF CANCER (2010)
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
J-F Rossi et al.
BRITISH JOURNAL OF CANCER (2010)
Breastfeeding and risk of epithelial ovarian cancer
Susan J. Jordan et al.
CANCER CAUSES & CONTROL (2010)
Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk
Galina Lurie et al.
CANCER CAUSES & CONTROL (2010)
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Christoph Engel et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Indoleamine 2,3-Dioxygenase Is It an Immune Suppressor?
Hatem Soliman et al.
CANCER JOURNAL (2010)
Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response
Dong Liang et al.
CANCER RESEARCH (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Inherited Determinants of Ovarian Cancer Survival
Ellen L. Goode et al.
CLINICAL CANCER RESEARCH (2010)
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2010)
Pertuzumab for the treatment of ovarian cancer
Simon P. Langdon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Farletuzumab in epithelial ovarian carcinoma
Whitney A. Spannuth et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study
A. J. White et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2010)
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Jennifer A. Belisle et al.
MOLECULAR CANCER (2010)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
Llen L. Goode et al.
NATURE GENETICS (2010)
Common variants at 19p13 are associated with susceptibility to ovarian cancer
Kelly L. Bolton et al.
NATURE GENETICS (2010)
MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells
M. P. Ponnusamy et al.
ONCOGENE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target
Federica Barbieri et al.
JOURNAL OF ONCOLOGY (2010)
Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
Michael C. Schmid et al.
JOURNAL OF ONCOLOGY (2010)
Innate IL-17-producing cells: the sentinels of the immune system
Daniel J. Cua et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Ilona Kryczek et al.
BLOOD (2009)
Polymorphisms in NF-κB Inhibitors and Risk of Epithelial Ovarian Cancer
Kristin L. White et al.
BMC CANCER (2009)
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Renata A. Tassi et al.
BMC CANCER (2009)
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
Jessica N. McAlpine et al.
BMC CANCER (2009)
Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells
Fang-qiu Li et al.
BMC CANCER (2009)
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
W-F Cheng et al.
BRITISH JOURNAL OF CANCER (2009)
C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy)
Eva Lundin et al.
CANCER CAUSES & CONTROL (2009)
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
Kui Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
Ninke Leffers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
Mark J. Dobrzanski et al.
CLINICAL IMMUNOLOGY (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study
D. K. Armstrong et al.
EJC SUPPLEMENTS (2009)
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
Tomoko Inaba et al.
GYNECOLOGIC ONCOLOGY (2009)
Markers of inflammation and risk of ovarian cancer in Los Angeles County
Anna H. Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Ovarian Cancer Cells Induce Peripheral Mature Dendritic Cells to Differentiate Into Macrophagelike Cells In Vitro
Fangxue Chen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Pravin T. P. Kaumaya et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Jonathan Berek et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Babak Baban et al.
JOURNAL OF IMMUNOLOGY (2009)
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2
Honglin Song et al.
NATURE GENETICS (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Kiavash Movahedi et al.
BLOOD (2008)
Polymorphism in the IL18 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women
Rachel T. Palmieri et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer
Kimberly R. Kalli et al.
CANCER RESEARCH (2008)
MUC4, a Multifunctional Transmembrane Glycoprotein, Induces Oncogenic Transformation of NIH3T3 Mouse Fibroblast Cells
Sangeeta Bafna et al.
CANCER RESEARCH (2008)
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity
Eduardo Huarte et al.
CANCER RESEARCH (2008)
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer
Michael J. Callahan et al.
CLINICAL CANCER RESEARCH (2008)
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
Chirag A. Shah et al.
GYNECOLOGIC ONCOLOGY (2008)
Rationale for folate receptor alpha targeted therapy in high risk endometrial carcinomas
Monica Brown Jones et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
Angele L. M. Oei et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Mammaglobin B expression in human endometrial cancer
R. A. Tassi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D
Mathias Krockenberger et al.
JOURNAL OF IMMUNOLOGY (2008)
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
Je-In Youn et al.
JOURNAL OF IMMUNOLOGY (2008)
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls
V. Beral et al.
LANCET (2008)
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Francisco J. Quintana et al.
NATURE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
Peter M. Smith-Jones et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
NKG2D ligands:: key targets of the immune response
Segundo Gonzalez et al.
TRENDS IN IMMUNOLOGY (2008)
The NKG2D receptor: sensing stressed cells
Carlos Lopez-Larrea et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer
Melissa A. Merritt et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Involvement of SDF-1 alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma
Hiroaki Kajiyama et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity
Paul M. Ridker
NUTRITION REVIEWS (2007)
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells
Marcelo Hill et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Tumor immune escape mediated by indoleamine 2,3-dioxygenase
Maria Zamanakou et al.
IMMUNOLOGY LETTERS (2007)
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Richard Metz et al.
CANCER RESEARCH (2007)
P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy
Annechien Lambeck et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Characterisation of the new EpCAM-specific antibody HO-3:: implications for trifunctional antibody immunotherapy of cancer
P. Ruf et al.
BRITISH JOURNAL OF CANCER (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
PD-1 and its ligands in T-cell immunity
Mary E. Keir et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Adoptive T cell therapy for cancer in the clinic
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
Louis A. Dainty et al.
GYNECOLOGIC ONCOLOGY (2007)
Overexpression of mammaglobin B in epithelial ovarian carcinomas
Renata A. Tassi et al.
GYNECOLOGIC ONCOLOGY (2007)
Principles of adoptive T cell cancer therapy
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer:: Results of a prospective study with 147 patients
Elena Ioana Braicu et al.
GYNECOLOGIC ONCOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells
Hagen Kulbe et al.
CANCER RESEARCH (2007)
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer
Kathryn L. Terry et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
CD4 regulatory T cells in human cancer pathogenesis
Keith L. Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2006)
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference
Xiufen Zheng et al.
JOURNAL OF IMMUNOLOGY (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)
Subhash C. Chauhan et al.
MODERN PATHOLOGY (2006)
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer
Keith L. Knutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types
Huamin Wang et al.
MODERN PATHOLOGY (2006)
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
Zhenfeng Duan et al.
CLINICAL CANCER RESEARCH (2006)
Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways
T-H Wang et al.
ONCOGENE (2006)
Dendritic cells and tumor microenvironment: A dangerous liaison
Ingo Fricke et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
The role of folate receptor α in cancer development, progression and treatment:: Cause, consequence or innocent bystander?
Linda E. Kelemen
INTERNATIONAL JOURNAL OF CANCER (2006)
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells
Rongcun Yang et al.
CANCER RESEARCH (2006)
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels
J. M. Lancaster et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells
Francesca Fallarino et al.
JOURNAL OF IMMUNOLOGY (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype
Thorsten Hagemann et al.
JOURNAL OF IMMUNOLOGY (2006)
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
DH Munn
CURRENT OPINION IN IMMUNOLOGY (2006)
Induction of ovulation and ovarian cancer: a critical review of the literature
A Mahdavi et al.
FERTILITY AND STERILITY (2006)
Multiplicity and plasticity of natural killer cell signaling pathways
S Chiesa et al.
BLOOD (2006)
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas
AP Singh et al.
PROSTATE (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
HP Dong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
V Goodell et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
P Serafini et al.
SEMINARS IN CANCER BIOLOGY (2006)
Expression of synovial sarcoma x (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 Epitopes recognized by CD4+ T cells
D Valmori et al.
CLINICAL CANCER RESEARCH (2006)
Foxp3 expressing CD4(+) CD25(+) and CD8(+)CD28(-) T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma
Federica Meloni et al.
HUMAN IMMUNOLOGY (2006)
Adoptive T cell therapy of solid cancers
KL Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Role of folate receptor genes in reproduction and related cancers
H Elnakat et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
MS Patankar et al.
GYNECOLOGIC ONCOLOGY (2005)
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
TG Ehlen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Stromal cell-derived factor-1α (SDF-lα/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation
C Porcile et al.
EXPERIMENTAL CELL RESEARCH (2005)
Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis
S Bonovas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma
S Wei et al.
CANCER RESEARCH (2005)
The proinflammatory cytokine interleukin 1β and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation
S Frede et al.
CANCER RESEARCH (2005)
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients
M Ho et al.
CLINICAL CANCER RESEARCH (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers
SK Halder et al.
NEOPLASIA (2005)
Mechanisms of suppression by suppressor T cells
H von Boehmer
NATURE IMMUNOLOGY (2005)
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
N Parker et al.
ANALYTICAL BIOCHEMISTRY (2005)
Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell
B Perussia et al.
MOLECULAR IMMUNOLOGY (2005)
The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs
Jan Lubinski et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2005)
Expression of sperm protein 17 (Sp17) in ovarian cancer
JM Straughn et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer
S Baron-Hay et al.
CLINICAL CANCER RESEARCH (2004)
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
JS Berek et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Tumor necrosis factor-α in the pathogenesis and treatment of cancer
GM Anderson et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California
PK Mills et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma - From the Danish MALOVA ovarian cancer study
EVS Hogdall et al.
CANCER (2003)
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells
L Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas
HF Frierson et al.
HUMAN PATHOLOGY (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells:: Mediation of suppression by tryptophan metabolites
P Terness et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool
M Hofmann et al.
CANCER CYTOPATHOLOGY (2002)
Tumor necrosis factor or tumor promoting factor?
F Balkwill
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons
TM D'Hooghe et al.
HUMAN REPRODUCTION UPDATE (2002)
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
WP Zou et al.
NATURE MEDICINE (2001)
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
B Modan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
BWT Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Menstrual and reproductive factors in relation to ovarian cancer risk
L Titus-Ernstoff et al.
BRITISH JOURNAL OF CANCER (2001)
SNPs, protein structure, and disease
Z Wang et al.
HUMAN MUTATION (2001)
Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
RT Penson et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2000)
分享论文
